Carfilzomib injectable 10mg/30mg/60mg
Category: Pharmaceutical
Exhibitor: ORIENT EUROPHARMA CO., LTD.
Booth No: M426
Characteristic
The generic drug Carfilzomib (brand name Kyprolis®) is a second-generation proteasome inhibitor. Its mechanism of action involves irreversible and specific binding to the N-terminal threonine-containing active site of the 20S proteasome, functioning primarily as a targeted therapy for multiple myeloma. Kyprolis® was approved by the FDA in July 2012 and by the TFDA in August 2018. Currently, there is no generic version of this drug available on the Taiwan market.
Other Products
Products you may be interested in
Highest Rated Products